Sugi Predict

Sugi Predict / Compounds / SCHEMBL5052909

SCHEMBL5052909

SCHEMBL5052909

CC(C)(C)c1ccc(NCC(C(CCC(=O)O)C(=O)O)[PH](=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 6/20 0.40
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ EPHX2 P34913 2/20 0.37
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ GFER P55789 1/20 0.34
▸ GCGR P47871 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ ADCY6 O43306 1/20 0.33
▸ ADCY3 O60266 1/20 0.33
▸ ADCY9 O60503 1/20 0.33
▸ ADCY5 O95622 1/20 0.33
▸ ADCY8 P40145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056464 0.88 FFAR1 (0.46) EPHX2POLBFFAR1
SCHEMBL5052937 0.86 FFAR1 (0.43) POLBGAAMAPTSMN1; SMN2ALDH1A1
SCHEMBL5054407 0.86 FFAR1 (0.38) NR1H4SMN1; SMN2ALDH1A1FFAR1
SCHEMBL5053312 0.86 CYP1A1 (0.41) CA1CA2POLBGAAALDH1A1
SCHEMBL5053067 0.85 POLB (0.43) CA1CA2POLB
SCHEMBL5052977 0.85 GAA (0.41) POLBGAAALDH1A1CYP3A4FFAR1
SCHEMBL5057974 0.84 FFAR1 (0.43) POLBGAAALDH1A1FFAR1
SCHEMBL5051107 0.84 FOLH1 (0.41) POLBFFAR1
SCHEMBL5059934 0.83 FFAR1 (0.46) POLBGAAMAPTSMN1; SMN2NPSR1
SCHEMBL5053173 0.80 MAPT (0.42) POLBGAAMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1066297-B1 PHOSPHINIC ACID DERIVATIVES GUILFORD PHARM INC (US) 2002-10-23 — — EP claimed
US-6395718-B1 RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GUILFORD PHARMACEUTICALS INC. 2002-05-28 — — US claimed
JP-2002509934-A — — 2002-04-02 — — JP claimed
EP-1066297-A1 PHOSPHINIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 2001-01-10 — — EP claimed
US-6121252-A N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES GUILFORD PHARMACEUTICALS INC. (US) 2000-09-19 — — US claimed
WO-1999050272-A1 PHOSPHINIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1999-10-07 — — WO claimed
US-20080311037-A1 Compounds which bind PSMA and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 — — US disclosed
EP-1571141-A2 Naaladase inhibitors useful as pharmaceutical compounds and compositions GUILFORD PHARMACEUTICALS INC. (US) 2005-09-07 — — EP disclosed
US-6806261-B2 CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT GUILFORD PHARMACEUTICALS INC. 2004-10-19 — — US disclosed
EP-1371367-A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases GUILFORD PHARMACEUTICALS INC. (US) 2003-12-17 — — EP disclosed
EP-1140048-B1 USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES GUILFORD PHARM INC (US) 2003-09-03 — — EP disclosed
US-20030083374-A1 NAALADase inhibitors useful as pharmaceutical compounds and compositions JACKSON PAUL F (US) 2003-05-01 — — US disclosed
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors SLUSHER BARBARA S (US) 2003-04-03 — — US disclosed
EP-1093453-A1 NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS GUILFORD PHARMACEUTICALS INC. (US) 2001-04-25 — — EP disclosed
WO-2001001974-A2 NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS GUILFORD PHARMACEUTICALS INC. (US) 2001-01-11 — — WO disclosed
EP-1066297-A1 PHOSPHINIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 2001-01-10 — — EP disclosed
US-6121252-A N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES GUILFORD PHARMACEUTICALS INC. (US) 2000-09-19 — — US disclosed
WO-2000038785-A2 METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2000-07-06 — — WO disclosed
WO-2000001668-A2 NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS GUILFORD PHARMACEUTICALS INC. (US) 2000-01-13 — — WO disclosed
WO-1999050272-A1 PHOSPHINIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1999-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors NAALAD2, DNPEP, DPP9 NR1H4 3220/4885CA1 372/4885CA2 382/4885
US-20080311037-A1 Compounds which bind PSMA and uses thereof FOLH1, PSMA1, BPHL NR1H4 321/4885CA1 253/4885CA2 267/4885
US-20030083374-A1 NAALADase inhibitors useful as pharmaceutical compounds and compositions NAALAD2, DNPEP, NAAA NR1H4 3978/4885CA1 227/4885CA2 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.